Pfizer Inc.: More Planning Certainty, Attractive Valuation, and Forecast Clarification!

Pfizer Inc. (PFE) reported strong growth in the second quarter of 2025. The company announced revenue of $14.7 billion, representing an operational increase of 10% compared to the same quarter last year. According to management, this positive development was driven by improved commercial execution and ongoing advancements in research and development (R&D). The adjusted EPS rose by 30% to $0.78. Meanwhile, experts had only expected revenue of $13.53 billion and EPS of $0.57 for the second quarter. While the revenue forecast for the entire...